Details of the Drug Combinations

General Information of This Drug (ID: DMCVXBE)

Drug Name

E-64D DMCVXBE

Synonyms

E64D; E64d; Aloxistatin; Aloxistatin [INN]; Aloxistatina; Aloxistatina [Spanish]; Aloxistatine; Aloxistatine [French]; Aloxistatinum; Aloxistatinum [Latin]; BRN 5354546; C17H30N2O5; CCRIS 1934; CHEMBL63440; E 64c ethyl ester; E 64d; EP 453; EST; EST (pharmaceutical); L5W337AOUR; Loxistatin; MLS000028372; NSC 694281; SMR000058552; UNII-L5W337AOUR

Indication

Disease Entry	ICD 11	Status	REF
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[1]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
E-64D + Panobinostat	DC66EIZ	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.